rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Reverses Chronic Amphetamine-Induced Behavioral Disturbances in Rats

RPEP-007712002Sikiric, Predrag; Jelovac, Nikola; Jelovac-Gjeldum, Andjelka; Dodig, Goran; Staresinic, Mario; Anic, Tomislav; Zoricic, Ivan; Rak, Davor; Perovic, Darko; Aralica, Gorana; Buljat, Gojko; Prkacin, Ingrid; Lovric-Bencic, Martina; Separovic, Jadranka; Seiwerth, Sven; Rucman, Rudolf; Petek, Marijan; Turkovic, Branko; Ziger, Tihomil; Boban-Blagaic, Alenka; Bedekovic, Vlado; Tonkic, Ante; Babic, Slaven
Animal StudyPreliminary evidence
The takeaway

BPC-157 attenuated tolerance, sensitization, and withdrawal behaviors from chronic amphetamine exposure in rats, demonstrating comprehensive protection against stimulant drug-induced brain changes.

Triple protection

BPC-157 attenuated tolerance AND sensitization AND withdrawal from chronic amphetamine — comprehensive protection against all stimulant-induced brain changes

What the researchers found

BPC-157 attenuated chronic amphetamine-induced tolerance, behavioral sensitization, and withdrawal disturbances in rats, demonstrating comprehensive dopamine system stabilization against stimulant drug-induced neuroplasticity.

Why it matters

Stimulant addiction (amphetamine, methamphetamine) is devastating and has limited treatments. A peptide that comprehensively protects against chronic stimulant brain changes could transform addiction medicine.

How the study worked

Animal study in rats with chronic amphetamine exposure. BPC-157 co-administered at microgram and nanogram doses. Tolerance, sensitization (cross-sensitization), and withdrawal behaviors measured across multiple timepoints.

What this study cannot tell us

Rat model. Chronic amphetamine differs from human addiction patterns. The specific dopamine system mechanisms were not fully characterized.

How to read the evidence

Preliminary animal evidence with comprehensive behavioral characterization across multiple chronic amphetamine effects and two BPC-157 dose levels.

When this study was published

Published in 2002. BPC-157's dopamine-stabilizing and neuroprotective effects have been further confirmed in subsequent addiction and neuropharmacology studies.

The bigger picture

BPC-157's ability to stabilize the dopamine system against chronic stimulant disruption is consistent with its broader neuroprotective profile. A dopamine stabilizer rather than a blocker or agonist represents a novel addiction treatment concept.

Questions still open

  • Could BPC-157 help methamphetamine addiction treatment?
  • Does it work after addiction is established or only preventively?
  • What is the molecular mechanism of BPC-157's dopamine stabilization?

Common questions

Can BPC-157 help with stimulant addiction?
In rats, it protected against all the brain changes caused by chronic amphetamine: tolerance (needing more drug), sensitization (enhanced certain responses), and withdrawal symptoms. This is remarkable comprehensive protection.
How does it work differently from other addiction drugs?
Most addiction drugs either block dopamine (causing their own side effects) or substitute for the drug. BPC-157 appears to stabilize the dopamine system — keeping it functioning normally despite the drug's disruption. This is a fundamentally different, potentially better approach.

Read the original research

Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.

Acta pharmacologica Sinica, 23(5), 412-22

View on PubMed ↗

Citation

Sikiric, Predrag; Jelovac, Nikola; Jelovac-Gjeldum, Andjelka; Dodig, Goran; Staresinic, Mario; Anic, Tomislav; Zoricic, Ivan; Rak, Davor; Perovic, Darko; Aralica, Gorana; Buljat, Gojko; Prkacin, Ingrid; Lovric-Bencic, Martina; Separovic, Jadranka; Seiwerth, Sven; Rucman, Rudolf; Petek, Marijan; Turkovic, Branko; Ziger, Tihomil; Boban-Blagaic, Alenka; Bedekovic, Vlado; Tonkic, Ante; Babic, Slaven. (2002). Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.. Acta pharmacologica Sinica, 23(5), 412-22.